Back to search

Article

Etoposide–Platinum Rechallenge in Small Cell Lung Cancer Worth More Application: A Multicenter Study and Web-Based Predictive Model

2026-04-22

Abstract excerpt

<title>Abstract</title> <p>Objective Guidelines generally recommend platinum rechallenge for patients with small cell lung cancer (SCLC) who progress more than 6 months after first-line platinum-based chemotherapy. However, clinical practice indicates therapeutic benefit in patients with a 3-6-month chemotherapy-free interval (CTFI), warranting re-evaluation particularly in the immunotherapy era. This study aime...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e4f0903c-d55c-5ca7-9310-e397dead4fbd
DOI
10.21203/rs.3.rs-9293073/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Etoposide–Platinum Rechallenge in Small Cell Lung Cancer Worth More Application: A Multicenter Study and Web-Based Predictive ModelDOI 10.21203/rs.3.rs-9293073/v1
Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity
Construction of a Prognostic Model for Extensive-Stage Small Cell Lung Cancer Patients Undergoing Immune Therapy in Real-World Settings and Prediction of Treatment Efficacy Based on Response Status at Different Time PointsSemantic proximity
Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.Semantic proximity
[Annual therapeutic advances in advanced non-small cell lung cancer in 2024].Semantic proximity
Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic or Unresectable EGFR-Mutated Non-Small Cell Lung Cancer Previously Treated with Osimertinib and Platinum-Based Chemotherapy.Semantic proximity
First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.Semantic proximity
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small-cell lung cancer: protocol of IRICO studySemantic proximity
Real-world outcomes among patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first-line setting.Semantic proximity
The BREATHE project: An observational prospective cohort integrating clinical data, blood samples and tumor tissue from newly diagnosed patients with lung cancerSemantic proximity
Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Starting First-Line Systemic Therapy in the United KingdomSemantic proximity
Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England.Semantic proximity
Select a neighboring publication to make it the new centre.